Kathleen Oare Lindell1. 1. Associate Professor of Medicine, Clinical Nurse Specialist, Executive Director SUPPORT Program, University of Pittsburgh Dorothy P. & Richard P. Simmons, Center for Interstitial Lung Disease at UPMC, NW 628, UPMC Montefiore, 3459 Fifth Avenue, Pittsburgh, PA 15213, lindellko@upmc.edu.
Abstract
A PURPOSE OF REVIEW: Interstitial lung diseases (ILDs) cause unpredictable degrees of fibrosis and inflammation in the lungs leading to functional decline and varying symptom burden for patients. Some patients may live for years and be responsive to therapy and others disease trajectory may be shorter and similar to patients with lung cancer. This ultimately affects the patient's quality of life as well as their caregiver(s). B RECENT FINDINGS: Nonpharmacological therapies play an important role in treatment of interstitial lung disease. These include symptom management, pulmonary rehabilitation, oxygen therapy, and palliative care. While ILDs are associated with high morbidity and mortality, different models of care exist globally. New tools help clinicians identify and address palliative care needs in daily practice and specialty nurses and ILD centers can optimize care. C SUMMARY: This paper provides an overview of nonpharmacological therapies available for patients with interstitial lung disease.
A PURPOSE OF REVIEW: Interstitial lung diseases (ILDs) cause unpredictable degrees of fibrosis and inflammation in the lungs leading to functional decline and varying symptom burden for patients. Some patients may live for years and be responsive to therapy and others disease trajectory may be shorter and similar to patients with lung cancer. This ultimately affects the patient's quality of life as well as their caregiver(s). B RECENT FINDINGS: Nonpharmacological therapies play an important role in treatment of interstitial lung disease. These include symptom management, pulmonary rehabilitation, oxygen therapy, and palliative care. While ILDs are associated with high morbidity and mortality, different models of care exist globally. New tools help clinicians identify and address palliative care needs in daily practice and specialty nurses and ILD centers can optimize care. C SUMMARY: This paper provides an overview of nonpharmacological therapies available for patients with interstitial lung disease.
Authors: Kathleen O Lindell; Zhan Liang; Leslie A Hoffman; Margaret Q Rosenzweig; Melissa I Saul; Joseph M Pilewski; Kevin F Gibson; Naftali Kaminski Journal: Chest Date: 2015-02 Impact factor: 9.410
Authors: Christopher J Ryerson; Cindy Cayou; Fiona Topp; Lana Hilling; Pat G Camp; Pearce G Wilcox; Nasreen Khalil; Harold R Collard; Chris Garvey Journal: Respir Med Date: 2013-12-04 Impact factor: 3.415
Authors: Sabrina Bajwah; Joy R Ross; Janet L Peacock; Irene J Higginson; Athol U Wells; Amit Suresh Patel; Jonathan Koffman; Julia Riley Journal: Thorax Date: 2012-12-01 Impact factor: 9.139
Authors: Kim Beernaert; Joachim Cohen; Luc Deliens; Dirk Devroey; Katrien Vanthomme; Koen Pardon; Lieve Van den Block Journal: Respir Med Date: 2013-06-27 Impact factor: 3.415
Authors: Adelle S Jee; Robert Sheehy; Peter Hopkins; Tamera J Corte; Christopher Grainge; Lauren K Troy; Karen Symons; Lissa M Spencer; Paul N Reynolds; Sally Chapman; Sally de Boer; Taryn Reddy; Anne E Holland; Daniel C Chambers; Ian N Glaspole; Helen E Jo; Jane F Bleasel; Jeremy P Wrobel; Leona Dowman; Matthew J S Parker; Margaret L Wilsher; Nicole S L Goh; Yuben Moodley; Gregory J Keir Journal: Respirology Date: 2020-11-24 Impact factor: 6.424